BioGaia probiotic strains – L. reuteri
BioGaia: The Forefront of Microbial Health Innovation
BioGaia is a Swedish healthcare company that has been at the forefront of microbiome research for over three decades.
Our dedication to understanding and harnessing the power of beneficial bacteria has led us to develop probiotic products featuring Lactobacillus reuteri*, renowned as one of the most scientifically validated probiotics globally.
Note, there has been a taxonomy name change from Lactobacillus to Limosilactobacillus and you will find both names throughout the content.
Science is at the core of everything we do.
BioGaia’s global research network
As a pioneer in the field, BioGaia has been at the forefront of probiotic and microbiome research for more than 30 years.
Our team of microbiologists, metabolism experts, process experts, and those responsible for clinical development collaborate with a comprehensive international network of leading researchers and doctors.
Research institutions and these partnerships allow us to validate our rationally designed probiotic formulations through rigorous clinical trials. Many of our trials are double-blind, randomised, and placebo-controlled, ensuring robust scientific evidence.
Probiotic Science: Expert Insights
In this short video, leading experts in pediatrics, gastroenterology, and oral health share what truly matters when selecting a probiotic. Discover why not all probiotics are the same—and how to guide patients toward the option that best supports their needs.
Pioneering microbiome research
BioGaia’s products all contain L. retueri, one of the most scientifically well-documented probiotics in the world. Health benefits and efficacy have been shown in numerous clinical studies.
To date the efficacy and safety of BioGaia’s different strains of L. reuteri have been shown in:
BioGaia’s probiotic endorsements
Guidelines for recommendation in Adults
Introducing L. reuteri: One of the world’s most studied probiotic
BioGaia’s products contain unique and patented strains of the lactic acid bacteria Limosilactobacillus reuteri, formerly known as Lactobacillus reuteri.
L. reuteri is a probiotic species whose natural habitat is the human body. Passed from generation to generation during childbirth and breastfeeding, L. reuteri has co-evolved with humans since the beginning of time.
Every product from BioGaia contains unique L. reuteri strains that provide their own distinct health benefits.
Unfortunately, research shows that modern lifestyles have largely eradicated L. reuteri from the human microbiota in many people living a modern, Western lifestyle. By reintroducing L. reuteri through probiotic solutions, this crucial bacterial culture helps restore the potential of the human microbiome.
Why recommend probiotic products with L. reuteri ?
- L. reuteri is one of few bacterial species that has developed in symbiosis with humans. Due to this it naturally colonises and has a strong adaptation.
- L. reuteri strains survive through the whole GI tract.
- BioGaia’s products with L. reuteri are manufactured under controlled conditions and of the highest quality and are 100 % safe to use.
- The number of live bacteria is guaranteed until expiry.
- Efficacy and safety are tested and documented in the target populations, from newborns to the elderly.
- Our probiotics contain viable freeze-dried L. reuteri.
- The probiotic bacteria are always defined at the strain level.
L. reuteri reaches the gut alive
Probiotics originating from humans, like L. reuteri, possess a unique advantage as they have evolved alongside our physiology, potentially fostering a more symbiotic relationship with our gut microbiota.
This intimate co-evolution may enhance their ability to colonise effectively and exert targeted benefits within the human digestive system, making them particularly effective in promoting gut health.
Live bacteria must survive the journey through the acidic environment of the stomach to reach the gut alive. Our clinical studies show that our carefully selected probiotic strains, such as L. reuteri, are proven to survive and reach the gut alive.
Lactobacillus reuteri
Stringent quality standards
From state-of-the-art manufacturing to storage and distribution, we follow strict guidelines. Our quality control measures ensure that every batch meets safety and efficacy standards.
Individually fermented and freeze-dried, the bacteria in our products remain dormant until they encounter saliva and reach a higher temperature, at which point they awaken, are clinically proven to be ‘alive’, and begin their probiotic effects.
Clinically proven safe for all ages
L. reuteri from BioGaia has been widely studied in clinical trials and has been shown to have probiotic, health-promoting effects in both children and adults.
Numerous studies and meta-analyses have verified the safety of our L. reuteri strains for human consumption among individuals of all ages.
BioGaia Products
BioGaia offers a range of probiotic products designed to support individuals at every stage of life, from newborns to adults.
Infants & Children - References
CruchetS, et al. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. [Guíaibero-latinoamericanadeprácticaclínicapara elusodebióticosengastroenterología,hepatologíaynutriciónpediátricas:capítuloprobióticos]. Bol Med Hosp Infant Mex.2025;82(Supl5):1-50. doi:10.24875/BMHIM.M25000043.(Prevention and Management).
Szajewska H, et al. Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 2023;76(2):232-247. doi:10.1097/MPG.0000000000003633.
Guarner F, et al. World Gastroenterology Organisation Global Guideline: Probiotics and prebiotics. 2023. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pd
Indrio F, et al. Management of the Most Common Functional Gastrointestinal Disorders in Infancy: The Middle East Expert Consensus. Pediatr Gastroenterol Hepatol Nutr. 2021;24(4):325-336. doi:10.5223/pghn.2021.24.4.325.
Hojsak I, et al. European guidance on paediatric use of probiotics states that benefits are limited to several conditions and urges caution with specific vulnerable groups. (Review.) Acta Paediatr. 2018;107:927-937.
Cameron D, et al. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. World J Gastroenterol. 2017;23(45):7952-7964. doi:10.3748/wjg.v23.i45.7952.
Cruchet S, et al. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. [Guía ibero-latinoamericana de práctica clínica para el uso de bióticos en gastroenterología, hepatología ynutrición pediátricas: capítulo probióticos]. Bol Med Hosp Infant Mex. 2025;82(Supl 5):1-50. doi:10.24875/BMHIM.M25000043. (Prevention and Management).
Szajewska H, et al. Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 2023;76(2):232-247. doi:10.1097/MPG.0000000000003633.
Guarner F, et al. World Gastroenterology Organisation Global Guideline: Probiotics and prebiotics. 2023. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pd
Cruchet S, et al. Ibero-Latin American clinical practice guideline for the use of biotics in pediatric gastroenterology, hepatology, and nutrition: probiotics chapter. [Guía ibero-latinoamericana de práctica clínica para el uso de bióticos en gastroenterología, hepatología ynutrición pediátricas: capítulo probióticos]. Bol Med Hosp Infant Mex. 2025;82(Supl 5):1-50. doi:10.24875/BMHIM.M25000043. (Prevention and Management). Szajewska H, et al. Probiotics for the Management of Pediatric Gastrointestinal Disorders: Position Paper of the ESPGHAN Special Interest Group on Gut Microbiota and Modifications. J Pediatr Gastroenterol Nutr. 2023;76(2):232-247. doi:10.1097/MPG.0000000000003633. Guarner F, et al. World Gastroenterology Organisation Global Guideline: Probiotics and prebiotics. 2023. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pd Cameron D, et al. Probiotics for gastrointestinal disorders: Proposed recommendations for children of the Asia-Pacific region. World J Gastroenterol. 2017;23(45):7952-7964. doi:10.3748/wjg.v23.i45.7952. Iramain R, et al. [Consensus guideline on acute gastroenteritis in the emergency department. Emergency Medicine Committee of SLACIP (Latin American Society of Pediatric Intensive Care)]. 2017 Pediatr a(Asunci n). 44:249-258. doi: 10.18004/ped.2017.diciembre.249-258 (abstract in English). Lo Vecchio A, et al. An international consensus report on a new algorithm for the management of infant diarrhoea. Acta Paediatr. 2016;105(8):e384-e389. doi:10.1111/apa.13432. Guarino A, et al. Universal Recommendations for the Management of Acute Diarrhea in Nonmalnourished Children. J Pediatr Gastroenterol. Nutr. 2018;67(5):586-593. doi:10.1097/MPG.0000000000002053. Society of Microecology, Chinese Preventive Medical Association, 2024. Evidence-based guideline for pediatric clinicalapplication of probiotics. CPMA (Chinese Preventive Medical Association, Society of Microecology)
Adults - References
Guarner F, et al. World Gastroenterology Organisation Global Guideline: Probiotics and prebiotics. 2023. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pd
• Co-adjuvant therapy for
H. pylori eradication
Supported by 1 clinical guideline
Guarner F, et al. World Gastroenterology Organisation Global Guideline: Probiotics and prebiotics. 2023. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pd
• Functional constipation
Supported by 1 clinical guideline
Guarner F, et al. World Gastroenterology Organisation Global Guideline: Probiotics and prebiotics. 2023. https://www.worldgastroenterology.org/UserFiles/file/guidelines/probiotics-and-prebiotics-english-2023.pd
Herrera D, et al. Prevention and treatment of peri-implant diseases—The EFP S3 level clinical practice guideline. J Clin Periodontol.2023;50(S26):4-76. doi:10.1111/jcpe.13823.